Translating Proteomics Episode 12 – A New Era in Alzheimer’s Research with Sarah DeVos
Nautilus Biotechnology
November 14, 2024
On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer’s research with special guest and Curie Bio Drug Maker in Residence, Dr. Sarah DeVos. Their conversation focuses on:
- The impact of molecular diagnostics on Alzheimer’s research
- Recent Alzheimer’s drug approvals
- The future of Alzheimer’s research
Find this episode on Apple Podcasts, Spotify, or YouTube.
Chapters
00:00 – Introduction
01:54 – Why Sarah began studying Alzheimer’s
03:39 – Current tools and needs for future Alzheimer’s diagnostics
09:52 – Recent drug approvals in the Alzheimer’s space and their relationship to diagnostics
14:26 – Is it possible to develop biomarkers that detect Alzheimer’s at its earliest stages?
16:36 – What is limiting the development of new Alzheimer’s biomarkers?
17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer’s
19:33 – The genetics of Alzheimer’s
22:19 – Novel approaches to identifying and understanding Alzheimer’s pathology
25:54 – Where can proteomics advance Alzheimer’s research?
31:25 – The role of proteomics in Alzheimer’s animal models
34:33 – Sarah’s hopes for the next 10 years of Alzheimer’s research
41:39 – Outro
Resources
Dominant Inherited Alzheimer’s Network (DIAN) trials research updates
o In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer’s disease.
Amyloid plaque reducing clinical trials:
o Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease (Haeberlein et al. 2022)
o Lecanemab in Early Alzheimer’s Disease (Van Duck et al. 2022)
o Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer’s disease
Resurrecting the Mysteries of Big Tau (Fischer and Baas 2021)
o Review covering a potentially neuro-protective form of tau called “Big tau”
o Paper linking the NRN1 protein to cognitive resilience in Alzheimer’s
MORE ARTICLES
